NCT01647971 - Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Non-Hodgkins LymphomaB-cell LymphomaWaldenstrom's MacroglobulinemiaMarginal Zone LymphomaChronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Primary Central Nervous System Lymphoma

Interventions

DRUG

Ublituximab

Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)

Trial Locations (8)

10022

TG Therapeutics Investigational Trial Site, New York

20817

TG Therapeutics Investigational Trial Site, Bethesda

30607

TG Therapeutics Investigational Trial Site, Athens

31201

TG Therapeutics Investigational Trial Site, Macon

35805

TG Therapeutics Investigational Trial Site, Huntsville

38120

TG Therapeutics Investigational Trial Site, Memphis

72401

TG Therapeutics Investigational Trial Site, Jonesboro

07962

TG Therapeutics Investigational Trial Site, Morristown

All Listed Sponsors

lead

TG Therapeutics, Inc.

INDUSTRY